The Pre-Travel Consultation

CDC Health Information for International Travel 2010

Volumn , Issue , 2009, Pages 19-241

  Acosta, Rebecca W ^a   Atkinson, William ^m   Kroger, Andrew ^m   Wiersma, Steven T ^m   Chaves, Sandra S ^m   Mintz, Eric ^m   Gershman, Mark ^m   Schroeder, Betsy ^m   Staples, J Erin ^m   Jentes, Emily S ^m   Marano, Nina ^m   Cohn, Amanda ^m   Jackson, Michael L ^m   Rupprecht, Charles E ^m   Shlim, David R ^b   Tiwari, Tejpratap S P ^m   Dunne, Eileen F ^m   McCarron, Margaret ^m   Shay, David K ^m   Parker, Amy A ^m   Uzicanin, Amra ^m   Kutty, Preeta K ^m   Barskey, Albert E ^m   Gallagher, Kathleen M ^m   Skoff, Tami H ^m   Thomas, Cynthia G ^m   Nuorti, J Pekka ^m   Alexander, James P ^m   Wassilak, Steven ^m   Reef, Susan E ^m   Joyce, M Patricia ^m   Harriman, Kathleen H ^c   Chavez, Gilberto F ^d   Arguin, Paul M ^m   Steele, Stefanie F ^m   Tan, Kathrine R ^m   Mali, Sonja ^m   Pawlowski, Sean W ^e   Guerrant, Richard L ^e   Hackett, Peter H ^f   Yanni, Emad ^m   Carroll, I Dale ^g   LaRocque, Regina C ^h   Ryan, Edward T ^h   Warnock, Eli W ^m   Chosewood, L Casey ^m   Zielinski Gutierrez, Emily ^m   Wirtz, Robert A ^m   Nasci, Roger S ^m   Backer, Howard D ^c   Ansdell, Vernon E ⁱ   Galland, G Gale ^m   Barbeau, Deborah Nicolls ^j   Sleet, David A ^m   Wallace, L J David ^m   Malilay, Josephine ^m   Batts, Dahna ^m   Ansari, Armin ^m   Miller, Charles W ^m   Brown, Clive M ^m   Nord, Daniel A ^k   Reed, Christie M ^m   Green, Michael D ^m   Barnett, Elizabeth D ^l   LoBue, Philip ^m   Whatley, Amanda D ^m   Sommers, Theresa ^m   Brunette, Gary W ^m   Balaban, Victor ^m   more..

^a Traveler's Medical Service   (United States)

^b Jackson Hole Travel and Tropical Medicine   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Institute for Altitude Medicine   (United States)

^g The Pregnant Traveler   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF HAWAII   (United States)

^j TULANE UNIVERSITY   (United States)

^k Divers Alert Network   (United States)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884450866     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-070203481-7.50007-4     Document Type: Chapter

References (438)

1. Kozarsky PE The body of knowledge for the practice of travel medicine. J Travel Med 2006, 13(5):251-254.
2. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(12):1499-1539.
3. Spira A Setting the standard. J Travel Med 2003, 10(1):1-3.
4. Acosta RW, Wolfe MS Structure and organization of the pre-travel consultation and general advice for travelers. Travel medicine 2008, 35-45. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
5. Crockett M, Keystone J "I hate needles" and other factors impacting on travel vaccine uptake. J Travel Med 2005, 12(Suppl 1):S41-S46.
6. Edwards A, Elwyn G, Mulley A Explaining risks: turning numerical data into meaningful pictures. BMJ 2002, 324:827-830.
7. Gherardin T The pre-travel consultation- an overview. Australian Fam Phys 2007, 36(5):300-303.
8. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-15):1-48. CDC.
9. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-7):1-60. CDC.
10. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998, 47(RR-8):1-57. CDC.
11. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR07):1-21. CDC.
12. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR 17):1-59. CDC.
13. Plotkin SA Correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(3):401-409.
14. Murphy KR, Strunk RC Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985, 106(6):931-933.
15. Ball LK, Ball R, Pratt RD An assessment of thimerosal use in childhood vaccines. Pediatrics 2001, 107(5):1147-1154.
16. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
17. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR07):1-23. CDC.
18. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 2007, 56(41):1080-1084. CDC.
19. Bell BP, Feinstone SM Hepatitis A vaccine. Vaccines 2004, 269-297. W.B. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
20. Mutsch M, Spicher VM, Gut C, Steffen R Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 2006, 42(4):490-497.
21. Bacaner N, Stauffer B, Boulware DR, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004, 291(23):2856-2864.
22. Surveillance for acute viral hepatitis - United States, 2006. MMWR Surv Summ 2008, 57(SS02):1-24. CDC.
23. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362(9389):1065-1071.
24. Winokur PL, Stapleton JT Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992, 14(2):580-586.
25. Fiore AE Hepatitis A transmitted by food. Clin Infect Dis 2004, 38(5):705-715.
26. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(RR-16):1-25. CDC.
27. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(RR-16):1-23. CDC.
28. Mast E, Goldstein S, Ward JL Hepatitis B vaccine. Vaccines 2004, 299-337. W.B. Saunders, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
29. Simonsen L, Kane A, Lloyd J, et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999, 77(10):789-800.
30. Sagliocca L, Stroffolini T, Amoroso P, et al. Risk factors for acute hepatitis B: a case-control study. J Viral Hepat 1997, 4(1):63-66.
31. Lok AS, McMahon BJ Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004, 39(3):857-861.
32. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001, 50(RR-11):1-42. CDC.
33. Bock HL, Loscher T, Scheiermann N, et al. Accelerated schedule for hepatitis B immunization. J Travel Med 1995, 2(4):213-217.
34. Long GE, Rickman LS Infectious complications of tattoos. Clin Infect Dis 1994, 18(4):610-619. Review.
35. Mariano A, Mele A, Tosti ME, et al. Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy. J Med Virol 2004, 74(2):216-220.
36. Provisional Recommendations for Hepatitis B vaccination of adults - October 2005. [cited 2006 Oct 31]. Available from: . http://www.cdc.gov/nip/recs/provisional_recs/hepB_adult.pdf.
37. Gupta S, Medalla F, Omondi M, et al. Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin Infect Dis 2008, In press.
38. Ackers ML, Puhr ND, Tauxe RV, et al. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000, 283(20):2668-2673.
39. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention?. Clin Infect Dis 2004, 39(2):186-191.
40. Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002, 347(22):1770-1782.
41. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, 2(8569):1165-1169.
42. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991, 338(8774):1055-1059.
43. Typhoid immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1994, 43(RR-14):1-7. CDC.
44. Crump JA, Luby SP, Mintz ED The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
45. Beeching NJ, Clarke PD, Kitchin NR, et al. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 2004, 23(1):29-35.
46. Kollaritsch H, Que JU, Kunz C, et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997, 175(4):871-875.
47. Monath TP, Teuwen D, Cetron MS Yellow fever vaccine. Vaccines 2008, 959-1055. W.B. Saunders, Philadelphia. 5th ed. S. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
48. Monath TP, Cetron MS Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002, 34(10):1369-1378.
49. Van der Stuyft P, Gianella A, Pirard M, et al. Urbanisation of yellow fever in Santa Cruz, Bolivia. Lancet 1999, 353(9164):1558-1562.
50. Pan American Health Organization. EID Updates: Emerging and Reemerging Infectious Diseases, Region of the Americas. Vol. 5, No. 6 (25 Feb. 2008) Yellow fever in Paraguay: Mobilization continues. [cited 2008 Jun 8]. Available from: . http://www.paho.org/english/AD/DPC/CD/eid-eer-2008-02-25.htm.
51. Tomori O Yellow fever: The recurring plague. Crit Rev Clin Lab Sci 2004, 41(4):391-427.
52. Yellow fever vaccine: WHO position paper. Wkly Epidemiol Rec 2003, 40:349-360. World Health Organization.
53. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-Vax) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002, 66(5):535-541.
54. Pfsiter M, Kuersteiner O, Hilfiker H, et al. Immunogenicity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005, 72(3):339-346.
55. Ripoll C, Ponce A, Wilson MM, et al. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. Hum Vaccin 2008, 4(2):121-126.
56. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002, 51(RR-17):1-12. CDC.
57. World Health Organization. International Health Regulations. 2005. Geneva. [cited 2008 Jun 9]. Available from: . http://www.who.int/csr/ihr/en/index.html.
58. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
59. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007, 25(10):1727-1734.
60. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002, 51(44):989-993. CDC.
61. Marfin AA, Eidex Barwick R, Monath TP Yellow fever. Tropical infectious diseases: principles, pathogens, & practice 2005, 797-812. Mosby Elsevier, Philadelphia. 2nd ed. R.L. Guerrant, D.H. Walker, P.F. Weller (Eds.).
62. Hayes EB Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101(10):967-971.
63. Muñoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med 2008, 15(3):202-205.
64. Barwick R History of thymoma and yellow fever vaccination. Lancet 2004, 364(9438):936.
65. Cavalcanti DP, Salomao MA, Lopez-Camelo J, et al. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007, 12(7):833-837.
66. Nishioka Sde A, Nunes-Araujo FR F, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 1998, 3(1):29-33.
67. Suzano CE, Amaral E, Sato HK, et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006, 24(9):1421-1426.
68. Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993, 87(3):337-339.
69. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-15):1-48. CDC.
70. Kaplan JE, Nelson DB, Schonberger LB, et al. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ 1984, 62(4):585-590.
71. Inactivated Japanese encephalitis virus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993, 42(RR-01):1-16. CDC.
72. Marfin AA, Eidex RS, Kozarsky PE, et al. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005, 19(1):151-168.
73. Shlim DR, Solomon T Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002, 35(2):183-188.
74. Halstead SB, Tsai TF Japanese encephalitis vaccine. Vaccines 2004, 919-958. WB Saunders, Philadelphia. 4th edition. S.A. Plotkin, W.A. Orenstein (Eds.).
75. Solomon T Flavivirus encephalitis. N Engl J Med 2004, 351(4):370-378.
76. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370(9602):1847-1853.
77. Gambel JM, DeFraites R, Hoke C, et al. Japanese encephalitis vaccine: Persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995, 171(4):1074.
78. Japanese encephalitis vaccines. weekly Epidemiol Rec 2006, 81(34/35):331-340. W.H.O.
79. Martin DA, Biggerstaff BJ, Allen B, et al. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diag Lab Immunol 2002, 9(3):544-549.
80. Burke DS, Nisalak A, Ussery MA, et al. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 1985, 151(6):1093-1099.
81. Beasley DW C, Lewthwaite P, Solomon T Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008, 8(1):95-106.
82. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988, 319(10):608-614.
83. Defraites RF, Gambel JM, Hoke CH, et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 1999, 61(2):288-293.
84. Monath TP Japanese encephalitis vaccines: current vaccines and future prospects. Current topics in microbiology and immunology: Japanese encephalitis and West Nile virus infections 2002, 105-138. Springer-Verlag, Berlin. J.S. Mackenzie, A.D. Barrett, V. Deubel (Eds.).
85. Plesner AM Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 2003, 23(4):665-697.
86. Takahashi H, Pool V, Tsai T, et al. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000, 18(26):2963-2969.
87. Berg SW, Mitchell BS, Hanson RK, et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997, 24(2):265-266.
88. Sohn YM Japanese encephalitis immunization in Korea: past, present and future. Emerg Infect Dis 2000, 6(1):17-24.
89. Puthanakit T, Aurpibul L, Yoksan S, et al. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly retroactive antiretroviral therapy. Vaccine 2007, 25(49):8257-8261.
90. Yamada A, Imanishi J, Juang R-F, et al. Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases. Vaccine 1986, 4(1):32-34.
91. Raghunathan PL, Bernhardt SA, Rosenstein NE Opportunities for control of meningococcal disease in the United States. Ann Rev Med 2004, 55:333-353.
92. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
93. Greenwood B Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93(4):341-353.
94. Stephens DS, Greenwood B, Brandtzaeg P Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
95. American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. Red book: 2003 Report of the Committee on Infectious Disease. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003. p. 430-6.
96. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR07):1-21. CDC.
97. Koch S, Steffen R Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994, 1(1):4-7.
98. Wilder-Smith A Meningococcal disease: risk for international travellers and vaccine strategies. Travel Med Infect Dis 2008, 6(4):182-186.
99. Warrell MJ, Warrell DA Rabies and other lyssavirus diseases. Lancet 2004, 363(9413):959-969.
100. Strauss R, Granz A, Wassermann-Neuhold M, et al. A human case of travel-related rabies in Austria, September 2004. Euro Surveill 2005, 10(11):225-226.
101. Smith A, Petrovic M, Solomon T, et al. Death from rabies in a UK traveller returning from India. Euro Surveill 2005, 10(30):2761.
102. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis 2003, 36(1):60-63.
103. Human Rabies Prevention-United States, 2008: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008, 57(RR-03):1-28. CDC.
104. World Health Organ Tech Rep Ser 2005, 931:1-88. World Health Organization Expert Consultation on Rabies.
105. Rupprecht CE, Gibbons RV Clinical practice. Prophylaxis against rabies. N Engl J Med 2004, 351(26):2626-2635.
106. American Academy of Pediatrics. Diphtheria. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:p.277-81.
107. World Health Organization. WHO vaccine-preventable diseases monitoring system: 2005 global summary. Geneva, Switzerland: World Health Organization; 2005 Dec. 333 p. Report No.: WHO/IVB/2005.
108. Galazka A The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 2000, 181(Suppl 1):S2-S9.
109. Fatal respiratory diphtheria in a U.S. traveler to Haiti-Pennsylvania, 2003. MMWR Morbid Mortal Wkly Rep 2004, 52(53):1285-1286. CDC.
110. Wharton M, Vitek CR Diphtheria toxoid. Vaccines 2004, 211-228. W.B. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
111. Bisgard KM, Hardy IR B, Popovic T, et al. Respiratory diphtheria in the United States, 1980 through 1995. Am J Public Health 1998, 88(5):787-791.
112. Diphtheria acquired by U.S. citizens in the Russian Federation and Ukraine-1994. MMWR Morbid Mortal Wkly Rep 1995, 44(12):237. CDC, 243-4.
113. Farizo KM, Strebel PM, Chen RT, et al. Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis 1993, 16(1):59-68.
114. Availability of diphtheria antitoxin through an Investigational New Drug protocol. MMWR Morb Mortal Wkly Rep 2004, 53(19):413. CDC.
115. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC) for use of Tdap among health-care personnel. MMWR Recomm. Rep 2006, 55(RR-17):1-37.
116. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119(11):2677-2684.
117. Markowitz LE, Dunne EF, Saraiya MD, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee for Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 2007, 56(RR-2):1-24.
118. Fiore AE S, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morbid Mortal Wkly Rep 2008, 57(RR-7):1-60.
119. Ortiz JR, Wallis TR, Katz MA, et al. No evidence of avian influenza A (H5N1) among returning US travelers. Emerg Infect Dis 2007, 13(2):294-297.
120. Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003, 36(9):1095-1102.
121. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006, 166(20):2217-2221.
122. Naleway AL, Smith WJ, Mullooly JP Delivering influenza vaccine to pregnant women. Epidemiol Rev 2006, 28:47-53.
123. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000, 18(26):3040-3049.
124. Avian Influenza A virus infections of humans [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 May 23; cited 2008 Nov 30]. Available from: . http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm.
125. Diganosis: clinical signs and symptoms of influenza [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 Sep 12; cited 2008 Jul 28]. Available from: . http://www.cdc.gov/flu/professionals/acip/clinical.htm.
126. Heinonen OS, Shapiro S, Monson RR, et al. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 1973, 2(3):229-235.
127. NIH, CDC, HIVMA/IDSA. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [Internet]. Rockville (MD): AIDS Info; 2008. [cited 25 Jul 2008]. Available from: . http://www.aidsinfo.nih.gov/contentfiles/Adult_OI.pdf.
128. Lin JC, Nichol KL Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
129. Miotti PG Nelson KE, Dallabetta GA, et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989, 262(6):779-783.
130. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295(8):891-894.
131. Influenza A(H1N1) virus resistance to oseltamivir-2008 influenza season, southern hemisphere [Internet] 2008, W.H.O., World Health Organization, Geneva, [cited 2008 Nov 30]. Available from: http://www.who.int/csr/disease/influenza/H1N1webupdate20082008_kf.pdf.
132. CDC. Questions & answers: Influenza antiviral drug resistance [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 Jul 17; cited 2008 Nov 30]. Available from: . http://www.cdc.gov/flu/about/qa/antiviralresistance.htm.
133. Antivirals and antiviral resistant influenza [Internet] 2008, European Centre for Disease Prevention and Control (ECDC), ECDC, Stockholm, [cited 2008 Nov 30]; Available from: http://ecdc.europa.eu/Health%5Ftopics/influenza/antivirals.html.
134. WHO/ECDC frequently asked questions for Oseltamivir resistance [Internet] 2008, W.H.O., WHO, Geneva, [cited 2008 Nov 30]. Available from: http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html.
135. American Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 441-52.
136. Measles fact sheet. 2007 Nov [cited 2008 Nov 25] Available from: . http://www.who.int/mediacentre/factsheets/fs286/en/.
137. Progress toward measles elimination-Region of the Americas, 2002-2003. MMWR. Morbid Mortal Wkly Rep 2004, 53(14):304-306. CDC.
138. Measles-United States, January 1-April 25, 2008. MMWR Morb Mortal Wkly Rep 2008, 57:1-4. CDC.
139. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1998, 47(RR-8):1-57. CDC.
140. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morbid Mortal Wkly Rep 2008, 57(10):258-260. CDC.
141. Strebel PM, Papania MJ, dayan GH, et al. Measles vaccine. Vaccines 2008, 353-398. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
142. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005, 192(10):1686-1693.
143. Perry RT, Halsey NA The clinical significance of measles: a review. J Infect Dis 2004, 189(Suppl 1):S4-16.
144. Measles (rubeola) 2007 case definition. 2008 Jan 9 [cited 2008 Nov 25]. Available from: . http://www.cdc.gov/ncphi/disss/nndss/casedef/measles_current.htm.
145. American Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Long SL, Kimberlin DW, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
146. Recommended childhood and adolescent immunization schedule-United States, 2006. MMWR Morb Mortal Wkly Rep 2006, 54(52):Q1-Q4. CDC.
147. American Academy of Pediatrics. Mumps. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003. p. 464-8.
148. Updated recommendations for isolation of persons with mumps. MMWR Morbid Mortal Wkly Rep 2008, 57(40):1103-1105. CDC.
149. Global status of mumps immunization and surveillance. Wkly Epidemiol Rec 2005, 80(48):417-424. World Health Organization.
150. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1998, 47(RR-8):1-57. CDC.
151. Notice to readers: Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR Morbid Mortal Wkly Rep 2006, 55(22):629-630. CDC.
152. Measles prevention: recommendations of the Immunization Practices Advisory Committee on Infectious Diseases (ACIP). MMWR Morbid Mortal Wkly Rep 1989, 38(No. S-9):1-18. CDC.
153. Plotkin SA, Rubin S Mumps Vaccine. Vaccines 2008, 436-465. Elsevier Saunders, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
154. Watson JC, Hadler SC, Dykewicz CA, et al. CDC. Measles, mumps and rubella vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1998, 47(RR-8):1-57.
155. Council of State and Territorial Epidemiologists. Infectious Disease Committee. Revision of the surveillance case definition for mumps. [cited 2008 Nov 25] Available from: . http://www.cste.org/PS/2007ps/2007psfinal/ID/07-ID-02.pdf.
156. Harling R, White JM, Ramsay ME, et al. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005, 23(31):4070-4074.
157. Edwards KM, Decker MD Pertussis vaccines. Vaccines 2004, 471-528. W.B. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
158. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-17):1-37. CDC.
159. American Academy of Pediatrics. Pertussis. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 498-520.
160. Tiwari T, Murphy TV, Moran J Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep 2005, 54(RR-14):1-16.
161. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-7):1-25. CDC.
162. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1997, 46(RR-8):1-24. CDC.
163. Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(No. RR-9):1-38. CDC.
164. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 525-37.
165. Invasive pneumococcal disease in children 5 years after routine conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57(6):144-148. CDC.
166. Fedson DS, Scott JA G The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, 17(Supplement 1):S11-S18.
167. Pneumococcal conjugate vaccine for childhood immunisation-WHO position paper. Wkly Epidemiol Rec 2007, 82(12):93-104. W.H.O.
168. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
169. Greenwood B The epidemiology of pneumococcal infection in children in the developing world. Phil Trans R Soc Lond B Biol Sci 1999, 354(1384):777-785.
170. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement 2008, Clinical and Laboratory Standards Institute., Clinical and Laboratory Standards Institute, Wayne, PA, CLSI Document M100-S18.
171. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004, 39(9):1267-1284.
172. Sutter RW, Kew OM, Cochi SL Poliovirus vaccine-live. Vaccines 2008, 631-686. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
173. Plotkin SA, Vidor E Poliovirus Vaccine-Inactivated. Vaccines 2008, 605-630. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
174. Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases 2006, 97-110. CDC, Public Health Foundation, Washington, DC. 9th ed. W. Atkinson, J. Hamborsky, L. McIntyre, S. Wolfe (Eds.).
175. Progress toward interruption of wild poliovirus transmission-worldwide, January 2007-April 2008. MMWR Morbid Mortal Wkly Rep 2008, 57(18):489-494. CDC.
176. Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005. MMWR Morbid Mortal Wkly Rep 2006, 55(6):145-150. CDC.
177. Global case count. [cited 2008 Sept 16]. Available from: . org/casecount.asp. http://www.polioeradication.
178. Poliomyelitis prevention in the United States-updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR-5):1-22. CDC.
179. Poliomyelitis-United States, 1975-1984. MMWR Morbid Mortal Wkly Rep 1986, 35(11):180-182. CDC.
180. International Notes: Certification of poliomyelitis eradication-the Americas, 1994. MMWR Morbid Mortal Wkly Rep 1994, 43(39):720-722. CDC.
181. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of polio in the United States. JAMA 2004, 292(14):1696-1701.
182. Imported vaccine-associated paralytic poliomyelitis-United States, 2005. MMWR Morbid Mortal Wkly Rep 2006, 55(4):97-99. CDC.
183. Poliovirus infections in four unvaccinated children-Minnesota, August-October, 2005. MMWR Morbid Mortal Wkly Rep 2005, 54(41):1053-1055. CDC.
184. Laboratory surveillance for wild and vaccine-derived polioviruses. MMWR Morbid Mortal Wkly Rep 2008, 57(35):967-970. CDC.
185. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva 27-28 November 2007. Wkly Epidemiol Rec 2008, 83(3):25-35. World Health Organization.
186. Rubella. Epidemiology and prevention of vaccine-preventable diseases 2008, 159-174. CDC, Public Health Foundation, Washington (DC). 10th ed. W. Atkinson, J. Hamborsky, L. McIntyre, S. Wolfe (Eds.).
187. Reef SE, Redd SB, Abernathy E, et al. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission. Clin Infect Dis 2006, 43(Suppl 3):S126-S132.
188. Plotkin SA, Reef SE Rubella vaccine. Vaccines 2008, 735-771. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
189. Reef SE, Cochi SL The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006, 43(Suppl 3):S123-S125.
190. Meissner HC, Reef SE, Cochi S Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics 2006, 117(3):933-935.
191. Robertson SE, Featherstone DA, Gacic-Dobo M, et al. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003, 14(5):306-315.
192. Plotinsky RN, Talbot EA, Kellenberg JE, et al. Congenital rubella syndrome in a child born to Liberian refugees: clinical and public health perspectives. Clin Pediatr (Phila) 2007, 46(4):349-355.
193. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998, 47(RR-8):1-57.
194. Kroger AT, Atkinson WL, Marcuse EK, et al. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-15):1-48.
195. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55(RR-17):1-37.
196. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-3):1-34.
197. Roper MH, Vandelaer JH, Gasse FL Maternal and neonatal tetanus. Lancet 2007, 370(9603):1947-1959.
198. Wassilak SG F, Roper MH, Kretsinger K, Orenstein WA Tetanus toxoid. Vaccines 2008, 805-839. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
199. Vandelaer J, Birmingham M, Gasse F, et al. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003, 21(24):3442-3445.
200. Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization. Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-4):1-51.
201. Hsu SS, Groleau G Tetanus in the emergency department: a current review. J Emerg Med 2001, 20(4):357-365.
202. Pascual FB, McGinley EL, Zanardi LR, et al. Tetanus surveillance-United States, 1998-2000. MMWR Surveill Summ 2003, 52(3):1-8.
203. Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000, 69(3):292-301.
204. American Academy of Pediatrics. Tetanus (lockjaw). In: Pickering LK, Baker CH, Long SS, McMillan JA, editors. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006: p. 648-53.
205. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 2007, 56(RR-4):1-40. CDC.
206. Gershon AA, Takahasi M, Seward J Varicella vaccine. Vaccines 2004, 783-823. W.B. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
207. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002, 287(5):606-611.
208. Decline in annual incidence of varicella-selected states, 1990-2001. MMWR Morbid Mortal Wkly Rep 2003, 52(37):884-885. CDC.
209. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites-United States, 1995-2005. J Infect Dis 2008, 197(Suppl 2):S71-S75.
210. Immunization summary: The 2007 edition. [cited 2008 April 14]. Available from: . http://www.unicef.org/publications/files/Immunization_Summary_2007.pdf.
211. A new product (VariZIG) for postexposure prophylaxis of varicella available under an Investigational New Drug application expanded access protocol. MMWR Morbid Mortal Wkly Rep 2006, 55:1-2. CDC.
212. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004, 23(2):132-137.
213. Seward JF Update on varicella. Pediatr Infect Dis J 2001, 20(6):19-21.
214. Harpaz R, Ortega-Sanchez IR, Seward JF Prevention of herpes zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-05):1-30.
215. Malaria map application. [cited 2008 Nov 26]. Available from: . http://www.cdc.gov/malaria/risk_map/.
216. Malaria website. [cited 2008 Nov 26]. Available from: . http://www.cdc.gov/malaria/.
217. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008, 46(2):165-171.
218. Guinovart C, Navia MM, Tanner M, et al. Malaria: burden of disease. Curr Mol Med 2006, 6(2):137-140.
219. Mali S, Steele S, Slutsker L, et al. Malaria surveillance-United States, 2006. MMWR Surveill Summ 2008, 57(5):24-39.
220. Newman RD, Parise ME, Barber AM, et al. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med 2004, 141(7):547-555.
221. Leder K, Black J, O'Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004, 39(8):1104-1112.
222. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel surveillance network. Clin Infect Dis 2006, 43:1185-1193.
223. Kitchen AD, Chiodini PL Malaria and blood transfusion. Vox Sanguin 2006, 90(2):77-84.
224. Parise ME, Lewis LS Severe malaria: North American perspective. Tropical and parasitic infections in the ICU 2005, 17-38. Springer Science+ Buisness Media, Inc., New York. C. Feldman, G.A. Sarosi (Eds.).
225. Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005, 11(1):132-134.
226. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004, 329(7476):1212.
227. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(12):1499-1539.
228. Fradin MS, day JF Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002, 347(1):13-18.
229. Boggild AK, Parise ME, Lewis LS, et al. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007, 76(2):208-223.
230. Baird JK, Fryauff DJ, Hoffman SL Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003, 37(12):1659-1667.
231. Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006, 75(3):402-415.
232. Schwartz E, Parise M, Kozarsky P, et al. Delayed onset of malaria-implications for chemoprophylaxis in travelers. N Engl J Med 2003, 349(16):1510-1516.
233. Whitty CJ M, Edmonds S, Mutabingwa TK Malaria in pregnancy. BJOG 2005, 112(9):1189-1195.
234. Steffen R Epidemiology of travellers' diarrhoea. Scand J Gastroenterol Suppl 1983, 84:5-17.
235. Black RE Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990, 12(Suppl 1):S73-S79.
236. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001, 32(12):1706-1709.
237. Von Sonnenburg F, Tornieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000, 356(9224):133-134.
238. Shlim DR Update in traveler's diarrhea. Infect Dis Clin North Am 2005, 19(1):137-149.
239. DuPont HL, Ericsson CD Prevention and treatment of traveler's diarrhea. N Engl J Med 1993, 328(25):1821-1827.
240. Connor BA Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005, 41(Suppl 8):S577-S586.
241. Hoge CW, Gambel JM, Srijan A, et al. Trends in antimicrobial resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998, 26:341-345.
242. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized double blind clinical trial. Clin Infect Dis 2001, 33(11):1807-1815.
243. The state of the world's children 2008. [cited 2008 Nov 26]. Available from: . http://www.unicef.org/sowc08/.
244. Kosek M, Bern C, Guerrant R The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull WHO 2003, 81(3):197-204.
245. Guerrant R, Oria R, Bushen OY, et al. Global impact of diarrheal diseases that are sampled by travelers: the rest of the hippopotamus. Clin Infect Dis 2005, 41(Suppl 8):S524-S530.
246. Guerrant R, Kosek M, Moore S, et al. Magnitude and impact of diarrheal diseases. Arch Med Res 2002, 33(4):351-355.
247. Guerrant RL, Oriá RB, Moore SR, et al. Malnutrition as an enteric infectious disease, with long-term effects on child development. Nutr Rev 2008, 66(9):487-505.
248. Checkley W, Buckley G, Gilman RH, et al. The Childhood Malnutrition and Diarrhea Network. Multi-country analysis of the effects of diarrhea on childhood stunting. Internat J Epidemiol 2008, 37(4):816-830.
249. Hackett PH, Roach RC High-altitude illness. N Engl J Med 2001, 345(2):107-114.
250. Hackett PH, Roach RC High-altitude medicine. Wilderness medicine 2007, Mosby Elsevier, Philadelphia. 5th ed. P.S. Auerbach (Ed.).
251. Pollard AJ, Murdoch DR The high altitude medicine handbook 2003, Radcliffe Medical Press, Abingdon, UK. 3rd ed.
252. Hackett PH High altitude and common medical conditions. High altitude: an exploration of human adaptation 2001, 839-885. Marcel Dekker, Inc., New York. T.F. Hornbein, R.B. Schoene (Eds.).
253. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003, 349(17):1628-1635.
254. Johnson TS, Rock PB, Fulco CS, et al. Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984, 310(11):683-686.
255. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006, 145(7):497-506.
256. Waterhouse J, Reilly T, Atkinson G, et al. Jet lag: trends and coping strategies. Lancet 2007, 369(9567):1117-1129.
257. Dubocovich ML, Markowska M Functional MT1 and MT2 melatonin receptors in mammals. Endocrines 2005, 27(2):101-110.
258. Reid KJ, Chang AM, Zee PC Circadian rhythm sleep disorders. Med Clin North Am 2004, 88(3):631-651.
259. Waterhouse J, Edward B, Nevill A, et al. Do subjective symptoms predict our perception of jet lag?. Ergonomics 2000, 43(10):1514-1527.
260. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part 1, basic principles, shift work and jet lag disorders: An American Academy of Sleep Medicine Review. Sleep 2007, 30(11):1460-1483.
261. Jamieson AO, Zammit GK, Rosenberg RS, et al. Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2001, 2(5):423-430.
262. Daurat A, Benoit O, Buguet A Effects of zopiclone on the rest/activity rhythm after a westward flight across five time zones. Psychopharmacology 2000, 149(3):241-245.
263. Reilly T, Waterhouse J, Edwards B Jet lag and air travel: implications for performance. Clin Sports Med 2005, 24(2):367-380.
264. Herxheimer A Jet lag. Clin Evid 2005, 13:2178-2183.
265. Priesol AJ Motion Sickness 2008, UpToDate, Waltham MA. B.D. Rose (Ed.).
266. Takeda N, Morita M, Horii A, et al. Neural mechanisms of motion sickness. J Med Invest 2001, 48(1-2):44-59.
267. Benline TA, French J, Poole E Anti-emetic drug effects on pilot performance: granisetron vs. ondansetron. Aviat Space Environ Med 1997, 68(11):998-1005.
268. FDA. Pregnancy and lactation labeling. 2008 [cited 2008 Oct 8]. Available from: . http://www.fda.gov/cder/regulatory/pregnancy_labeling.
269. Ansart S, Pajot O, Grivois JP, et al. Pneumonia among travelers returning from abroad. J Travel Med 2004, 11(2):87-91.
270. Leder K, Sundararajan V, Weld L, et al. Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2003, 36(4):399-406.
271. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006, 354(2):119-130.
272. Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 2000, 31(2):433-438.
273. Weitzel EK, McMains KC, Rajapaksa S, et al. Aerosinusitis: pathophysiology, prophylaxis, and management in passengers and aircrew. Aviat Space Environ Med 2008, 79(1):50-53.
274. Zitter JN, Mazonson PD, Miller DP, et al. Aircraft cabin air recirculation and symptoms of the common cold. JAMA 2002, 288(4):483-486.
275. Schwela D Air pollution and health in urban areas. Rev Environ Health 2000, 15(1-2):13-42.
276. Luna LK, Panning M, Grywna K, et al. Spectrum of viruses and atypical bacteria in intercontinental air travelers with symptoms of acute respiratory infection. J Infect Dis 2007, 195(5):675-679.
277. Camps M, Vilella A, Marcos MA, et al. Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas. J Med Virol 2008, 80(4):711-715.
278. Redman CA, Maclennan A, Wilson E, et al. Diarrhea and respiratory symptoms among travelers to Asia, Africa, and South and Central America from Scotland. J Travel Med 2006, 13(4):203-211.
279. Rack J, Wichmann O, Kamara B, et al. Risk and spectrum of diseases in travelers to popular tourist destinations. J Travel Med 2005, 12(5):248-253.
280. Morgan J, Cano MV, Feikin DR, et al. A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg 2003, 69(6):663-669.
281. Leder K, Newman D Respiratory infections during air travel. Intern Med J 2005, 35(1):50-55.
282. Medina-Ramon M, Zanobetti A, Schwartz J The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. Am J Epidemiol 2006, 163(6):579-588.
283. Farhat SC, Paulo RL, Shimoda TM, et al. Effect of air pollution on pediatric respiratory emergency room visits and hospital admissions. Braz J Med Biol Res 2005, 38(2):227-235.
284. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006, 43(9):1185-1193.
285. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000, 356(9228):461-465.
286. Regulations (Standards-29 CFR): Bloodborne pathogens-1910.1030. [cited 2008 Apr 1]. Available from: . http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10051.
287. Preventing needlestick injuries in health care settings. [cited 2008 Apr 10]. Available from: . http://www.cdc.gov/niosh/2000-108.html#8.
288. National Clinicians' Post-Exposure Prophylaxis Hotline (PEPline). [cited 2007 Dec 20]. Available from: . http://www.ucsf.edu/hivcntr/PEPline/index.html.
289. Sepkowitz KA Occupationally acquired infections in health care workers. Part II. Ann Intern Med 1996, 125(11):917-928.
290. Romea S, Alkiza ME, Ramon JM, et al. Risk of occupational transmission of HIV infection among health care workers. Study in a Spanish hospital. Eur J Epidemiol 1995, 11(2):225-229.
291. EPINet-Exposure Prevention Information Network. Uniform needle stick and sharp object injury report. International Health Care Worker Safety Center, University of Virginia, USA. 1998. [2008 Nov 26]. Available from: . http://www.healthsystem.virginia.edu/internet/epinet/home.cfm.
292. Canadian Center for Occupational Health and Safety. Needlestick injuries. 2000. [cited 2007 Dec]. Available from: . http://www.ccohs.ca/oshanswers/diseases/needlestick_injuries.html.
293. Puro V, De Carli G, Petrosillo N, et al. Risk of exposure to blood borne infection for Italian healthcare workers, by job category and work area. Studio Italiano Rischio Occupazionale da HIV Group. Infect Control Hosp Epidemiol 2001, 22(4):206-210.
294. Prüss-üstün A, Rapiti E, Hutin Y Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Industr Med 2005, 48(6):482-490.
295. Bell DM Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med 1997, 102(5B):9-15.
296. Sagoe-Moses C, Pearson RD, Perry J, et al. Risks to health care workers in developing countries. N Engl J Med 2001, 345(7):538-541.
297. Panlilio AL, Cardo DM, Grohskopf LA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2005, 54(RR-9):1-17.
298. Updated information regarding antiretroviral agents used as HIV postexposure prophylaxis for occupational HIV exposures. MMWR Morb Mortal Wkly Rep 2007, 56(49):1291-1292. CDC.
299. Uslan DZ, Verk A Postexposure chemoprophylaxis for occupational exposure to Human Immunodeficiency Virus in traveling health care workers. J Travel Med 2005, 12(1):14-18.
300. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001, 50(RR-11):1-42. CDC.
301. Barnard DR, Xue RD Laboratory evaluation of mosquito repellents against Aedes albopictus, Culex nigripalpus and Ochlerotatus triseriatus (Diptera: Culicidae). J Med Entomol 2004, 41(4):726-730.
302. Barnard DR, Bernier UR, Posey KH, et al. Repellency of IR3535, KBR3023, para-menthane-3,8-diol, and deet to Black Salt Marsh mosquitoes (Diptera: Culicidae) in the Everglades National Park. J Med Entomol 2002, 39(6):895-899.
303. Fradin MS, Day JF Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002, 347(1):13-18.
304. Murphy ME, Montemarano AD, Debboun M, et al. The effect of sunscreen on the efficacy of insect repellent: a clinical trial. J Am Acad Dermatol 2000, 43(2 Pt 1):219-222.
305. Thavara U, Tawatsin A, Chompoosri J, et al. Laboratory and field evaluations of the insect repellent 3535 (ethyl butylacetylaminopropionate) and deet against mosquito vectors in Thailand. J Am Mosq Control Assoc 2001, 17(3):190-195.
306. Backer HD Field water disinfection. Wilderness medicine 2007, 1368-1417. Mosby, Philadelphia. 5th ed. P.S. Auerbach (Ed.).
307. Backer H, Hollowell J Use of iodine for water disinfection: iodine toxicity and maximum recommended dose. Environ Health Perspect 2000, 108(8):679-684.
308. Groh CD, MacPherson DW, Groves DJ Effect of heat on the sterilization of artificially contaminated water. J Travel Med 1996, 3(1):11-13.
309. Joyce TM, McGuigan KG, Elmore-Meegan M, et al. Inactivation of fecal bacteria in drinking water by solar heating. Appl Environ Microbiol 1996, 62(2):399-402.
310. Korich DG, Mead JR, Madore MS, et al. Effects of ozone, chlorine dioxide, chlorine, and monochloramine on Cryptosporidium parvum oocyst viability. Appl Environ Microbiol 1990, 56(5):1423-1428.
311. McGuigan KG, Joyce TM, Conroy RM, et al. Solar disinfection of drinking water contained in transparent plastic bottles: characterizing the bacterial inactivation process. J Appl Microbiol 1998, 84(6):1138-1148.
312. Marchin GL, Fina LR Contact and demand-release disinfectants. Crit Rev Environ Contr 1989, 19(4):227-290.
313. Sobsey MD. Managing water in the home: accelerated health gains from improved water supply. Geneva: World Health Organization, 2002. [cited 6 Feb 2007]. Available from: . http://www.who.int/water_sanitation_health/dwq/wsh0207/en/index.html.
314. World Health Organization and United Nations Children's Fund. The global water supply and sanitation assessment 2000 report. 2000. [cited 6 Feb 2007]. Available from: . http://www.who.int/water_sanitation_health/monitoring/globalassess/en/.
315. Kaplan LA Exposure to radiation from the sun. Wilderness medicine 2007, 351-371. Mosby, Philadelphia. 5th ed. P.S. Auerbach (Ed.).
316. McClean DI, Gallagher R Sunscreens. Use and misuse. Dermatol Clin 1998, 16(2):219-226.
317. Diffey BL, Grice J The influence of sunscreen type on photoprotection. Br J Dermatol 1997, 137(1):103-105.
318. Murphy ME, Montemarano AD, Debboun M, et al. The effect of sunscreen on the efficacy of insect repellent: a chemical trial. J Am Acad Dermatol 2000, 43:219-222.
319. Gu X, Wang T, Collins DM, et al. In vitro evaluation of concurrent use of commercially available insect repellent and sunscreen preparations. Br J Dermatol 2005, 152(6):1263-1267.
320. Han A, Maibach HI Management of acute sunburn. Am J Clin Dermatol 2004, 5(1):39-47.
321. Moran DS, Gaffin SL Clinical management of heat-related illnesses. Wilderness medicine 2007, Mosby, Philadelphia. 5th ed. P.S. Auerbach (Ed.).
322. Epstein Y, Moran DS Extremes of temperature and hydration. Travel medicine 2008, 413-422. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
323. Noakes TD The hyponatremia of exercise. Int J Sport Nutr 1992, 2(3):205-228.
324. Backer HD, Shopes E, Collins SL, et al. Exertional heat illness and hyponatremia in hikers. Am J Emerg Med 1999, 17(6):532-539.
325. McCauley RL, Killyon GW, Smith DJ, et al. Frostbite. Wilderness medicine 2007, Mosby, Philadelphia. 5th ed. P.S. Auerbach (Ed.).
326. Ansdell V Food-borne illness. Travel medicine 2008, 475-484. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
327. Isbister GK, Kiernan MC Neurotoxic marine poisoning. Lancet Neurol 2005, 4(4):219-228.
328. Sobel J, Painter J Illnesses caused by marine toxins. Clin Infect Dis 2005, 41(9):1290-1296.
329. Palafox NA, Jain LG, Pinano AZ, et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 1988, 259(18):2740-2742.
330. Schnorf H, Taurarii M, Cundy T Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002, 58(6):873-880.
331. Callahan M Bites, stings, and envenoming injuries. Travel medicine 2008, 463-474. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
332. Rabies. Zoonoses and communicable diseases common to man and animals 2003, 2:246-276. Anonymous., PAHO, Washington (DC), Chlamydioses, rickettsioses, and viruses. 3rd ed. P.N. Acha, B. Szyfres (Eds.).
333. Schalamon J, Ainoedhofer H, Singer G, et al. Analysis of dog bites in children who are younger than 17 years. Pediatrics 2006, 117(3):e374-e379.
334. Huff JL, Barry PA B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg Infect Dis 2003, 9(2):246-250.
335. Cohen JI, Davenport DS, Stewart JA, et al. B Virus Working Group. Recommendations for prevention of and therapy for exposure to B virus (Cercopithecine Herpesvirus 1). Clin Infect Dis 2002, 35(10):1191-1203.
336. Gold BS, Dart RC, Barish RA Bites of venomous snakes. N Engl J Med 2002, 347(5):347-356.
337. Warrell DA Treatment of bites by adders and exotic venomous snakes. BMJ 2005, 331(7527):1244-1247.
338. Nonfatal dog bite-related injuries treated in hospital emergency departments-United States, 2001. MMWR Morb Mortal Wkly Rep 2003, 52(26):605-610. CDC.
339. Loe J, Röskaft E Large carnivores and human safety: a review. Ambio 2004, 33(6):283-288.
340. Schalamon J, Ainoedhofer H, Singer G, et al. Analysis of dog bites in children who are younger than 17 years. Pediatrics 2006, 117(3):e374-e379.
341. Feldman KA, Trent R, Jay MT Epidemiology of hospitalizations resulting from dog bites in California, 1991-1998. Am J Public Health 2004, 94(11):1940-1941.
342. Dog-bite-related fatalities-United States, 1995-1996. MMWR Morb Mortal Wkly Rep 1997, 46(21):463-467. CDC.
343. Diaz JH The global epidemiology, syndromic classification, management, and prevention of spider bites. Am J Trop Med Hyg 2004, 71(2):239-250.
344. Gibbons RV Cryptogenic rabies, bats, and the question of aerosol transmission. Ann Emerg Med 2002, 39(5):528-536.
345. Anderson FA, Spencer FA Risk factors for venous thromboembolism. Circulation 2003, 107(23 Suppl 1):I9-16.
346. World Health Organization. WHO Research into Global Hazards of Travel (WRIGHT) project: Final Report of Phase I. Geneva (Switzerland): World Health Organization; 2007 [cited 2008 May 30]. Available from: . http://www.who.int/cardiovascular_diseases/wright_project/en.
347. Kuipers S, Cannegieter SC, Middeldorp S, et al. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007, 4(9):e290.
348. Goodacre S, Sutton AJ, Sampson FC Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med 2005, 143(2):129-139.
349. Kuipers S, Schreijer AJ, Cannegieter SC, et al. Travel and venous thrombosis: a systematic review. J Intern Med 2007, 262(6):615-634.
350. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):381S-453S.
351. Peden M, McGee K, Sharma G. The injury chart book: a graphical overview of the global burden of injuries [Internet]. [cited 2008 Nov 25] Geneva (Switzerland): World Health Organization; 2002. Available from: . http://www.who.int/violence:injury_prevention/publications/other_injury/chartb/en/.
352. U.S. Department of Commerce. The Office of Travel and Tourism Industries. 2007 United States resident travel abroad [cited 2008 Nov 25]. Available from: . outbound_overview.html. http://tinet.ita.doc.gov/outreachpages/outbound.general_information.
353. McInnes RJ, Williamson LM, Morrison A Unintentional injury during foreign travel: a review. J Travel Med 2002, 9(6):297-307.
354. U.S. Department of State. U.S. citizen deaths from non-natural causes by foreign country [cited 2006 June]. Available from: . http://travel.state.gov/law/family_issues/death/death_600.html.
355. Web-based Injury Statistics Query and Reporting System (WISQARS) [cited 2008 June]. Available from: . http://www.cdc.gov/ncipc/wisqars.
356. MacPherson DW, Guérillot F, Streiner DL, et al. Death and dying abroad: the Canadian experience. J Travel Med 2000, 7(5):227-233.
357. Hargarten SW, Baker TD, Guptill K Overseas fatalities of United States citizen travelers: an analysis of deaths related to international travel. Ann Emerg Med 1991, 20(6):622-626.
358. Peden M, Scurfield R, Sleet D, et al., editors. World report on road traffic injury prevention. Geneva (Switzerland): World Health Organization; 2004. [cited 2008 Nov 25]. Available from: . http://www.who.int/violence:injury_prevention/publications/road_traffic/world_report/en/.
359. Sleet DA, Branche CM Road safety is no accident. J Safety Res 2004, 35(2):173-174.
360. Carey MJ, Aitken ME Motorbike injuries in Bermuda: a risk for tourists. Ann Emerg Med 1996, 28(4):424-429.
361. Hargarten SW, Bouc GT Emergency air medical transport of U.S.-citizen tourists: 1988 to 1990. Air Med J 1993, 12(10):398-402.
362. Barss P, Smith GS, Baker SP, et al. Injury prevention: an international perspective 1998, Oxford University Press, New York.
363. Zaza S, Sleet DA, Shults RA, et al. Reducing injuries to motor vehicle occupants. The guide to community preventive services: what works to promote health? 2005, 329-384. Oxford University Press, New York. S. Zaza, P. Briss, K. Harris (Eds.).
364. The Association for International Road Travel. [cited 2008 Nov 25]. Available from: . http://www.asirt.org.
365. Commission for Global Road Safety. Make Roads Safe. [cited 2008 Nov 25] Available from: . http://www.makeroadssafe.org.
366. U.S. Department of State. Bureau of Consular Affairs [cited 2008 Nov 25]. Available from: . http://travel.state.gov/travel/travel_1744.html.
367. Krug EG, Dahlberg LL, Mercy JA, et al. World report on violence and health. Geneva (Switzerland): World Health Organization; 2002. [cited 2008 Nov 25]. Available from: . http://www.who.int/violence:injury_prevention/violence/world_report/en.
368. Jeannel D, Allain-Ioos S, Bonmarin I, et al. Les décès de français lors d'un séjour à l'étranger et leurs causes. Bull Epid Heb 2006, (23-4):166-168.
369. Ball DJ, Machin N Foreign travel and the risk of harm. Int J Inj Contr Saf Promot 2006, 13(2):107-115.
370. Cortes LM, Hargarten SW, Hennes HM Recommendations for water safety and drowning prevention for travelers. J Travel Med 2006, 13(1):21-34.
371. United Nations General Assembly. Resolution A/RES/62/244 Improving global road safety. Sixty-second session, agenda item 46. 87th Plenary meeting, 2008 March 31. Passed 2008 April.
372. Natural disasters: protecting the public's health 2000, Pan American Health Organization., Pan American Health Organization, Washington (DC), [cited 2006 Jun 21]. Available from: http://www.paho.org/English/dd/ped/SP575.htm.
373. Watson JT, Gayer M, Connolly MA Epidemics after natural disasters. Emerg Infect Dis 2007, 13(1):1-5.
374. The public health consequences of disasters 1997, Oxford University Press, New York. E.K. Noji (Ed.).
375. Young S, Balluz L, Malilay J Natural and technologic hazardous material releases during and after natural disasters: a review. Sci Total Environ 2004, 322(1-3):3-20.
376. Nukushina J Japanese earthquake victims are being exposed to high density of asbestos. We need protective masks desperately. Epidemiol Prev 1995, 19(63):226-227.
377. Schneider E, Hajjeh RA, Spiegel RA, et al. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA 1997, 277(11):904-908.
378. Brant M, Brown C, Burkhart J CDC. Mold prevention strategies and possible health effects in the aftermath of hurricanes and major floods. MMWR Recomm Rep 2006, 55(RR-8):1-27.
379. National Council on Radiation Protection and Measurements. Exposure of the population in the United States and Canada from natural background radiation. Report No 94. Bethesda (Md); 1987.
380. Eisenbud M, Gessel T Environmental radioactivity from natural, industrial, and military sources 1997, Academic Press, San Diego. 4th ed.
381. United Nations Scientific Committee on the Effects of Atomic Radiation. Annex J: Exposures and effects of the Chernobyl accident. In: Sources and effects of ionizing radiation; United Nations Scientific Committee on the Effects of Atomic Radiation. UNSCEAR 2000 Report to the General Assembly with Scientific Annexes. Volume II: Effects. New York: United Nations; 2000. p. 451-556.
382. Accidental radioactive contamination of human food and animal feeds: recommendations for state and local agencies 1998, U.S. Food and Drug Administration, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Rockville (MD), [cited 2006 Jun 22]. Available from: http://www.fda.gov/cdrh/dmqrp/84.html.
383. Bennett and Elliot's physiology and medicine of diving 2003, Saunders Ltd., London. 5th ed. A.O. Brubakk, T.S. Neuman (Eds.).
384. Moon RE Treatment of decompression illness. Diving medicine 2004, 195-223. Saunders, London. 4th ed. A.A. Bove, J. Davis (Eds.).
385. Sheffield PJ, Vann RD. Flying after recreational diving: workshop proceedings. Divers Alert Network. 2004 [cited 2008 Nov 25]. Available from: . http://www.diversalertnetwork.org/research/projects/fad/workshop/.
386. Thalmann ED DAN dive and travel medical guide 2003, Divers Alert Network, Durham, NC. rev. ed.
387. U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico 2006 report, 2006 January-December. 2007.
388. U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2004 report, 2004 January-December. 2005.
389. U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico 2005 report, 2005 January-December. 2006.
390. U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2003 report, 2003 January-December. 2005.
391. Reed CM The health-seeking traveler. Travel medicine 2008, 343-350. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
392. Merrell RC, Boucher D, Carabello L, et al. Medical tourism. Telemed J E Health 2008, 14(1):14-20.
393. Wapner J American Medical Association provides guidance on medical tourism. BMJ 2008, 337:a575.
394. Furuya EY, Paez A, Srinivasan A, et al. Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008, 46(8):1181-1188.
395. Oleksyn V. Top transplant surgeons involved in organ trafficking, expert says. The Associated Press [updated 2008 Feb 14]. Available from: . http://www.bookrags.com/news/top-transplant-surgeons-involved-in-moc/.
396. U.S. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. Rockville (MD): 2007. [cited 2008 Jul 22]. Available from: . http://www.ustransplant.org/annual_reports/current/.
397. Bishop R, Litch JA Medical tourism can do harm. BMJ 2000, 320(7240):1017.
398. O'Leary A Working vacation. Yale Alumni Magazine 2008, 71(5). [cited 2008 Oct 13]. Available from: http://www.yalealumnimagazine.com/issues/2008_05/notebook.html.
399. U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2004 report, 2004 January-December. 2005.
400. Merion RM, Barnes AD, Lin M, et al. Transplants in foreign countries among patients removed from the US transplant waiting list. Am J Transplant 2008, 8(4 Pt 2):988-996.
401. Harling R, Turbitt D, Millar M, et al. Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas. Public Health 2007, 121(10):734-741.
402. Newton PN, Green MD, Fernández FM, et al. Counterfeit anti-infective drugs. Lancet Infect Dis 2006, 6(9):602-613.
403. World Health Organization. Counterfeit medicines. Fact sheet no. 275. Nov. 2006 [updated 2006 Nov 14; cited 2008 Jun 6]. Available from: . http://who.int/mediacentre/factsheets/fs275/en.
404. Newton PN, Fernandez FM, Green MD Counterfeit and substandard antimalarial drugs. Travelers' malaria 2008, 331-342. BC Decker, Inc., Hamilton (Canada). 2nd ed. P. Schlagenhauf-Lawlor (Ed.).
405. Kollaritsch H, Que JU, Kunz C, et al. Safety and immunogenicity of live oral chlorera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997, 175(4):871-875.
406. Horowitz H Carbonaro CA. Inhibition of the Salmonella Typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992, 166(6):1462-1464.
407. Brachman PS, Metchock B, Kozarsky PE Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a vaccine strain. Clin Infect Dis 1992, 15(6):1057-1058.
408. Pappaioanou M, Fishbein DB, Dreesen DW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986, 314(5):280-284.
409. Matson PA, Luby SP, Redd SC, et al. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996, 54(3):229-231.
410. CDC. Sudden death in a traveler following halofantrine administration-Togo, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(9):169-70, 179.
411. Neely JL, Abate M, Swinker M, et al. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 1991, 77(3):416-420.
412. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006, 43(9):1185-1193.
413. Jung P, Banks RH Tuberculosis risk in US Peace Corps volunteers, 1996 to 2005. J Travel Med 2008, 15(2):87-94.
414. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000, 356(9228):461-465.
415. Haley CA, Cain KP, Yu C, et al. Risk-based screening for latent tuberculosis infection. South Med J 2008, 101(2):142-149.
416. Al-Jahdali H, Memish ZA, Menzies D Tuberculosis in association with travel. Int J Antimicrob Agents 2003, 21(2):125-130.
417. Johnston VJ, Grant AD Tuberculosis in travellers. Travel Med Infect Dis 2003, 1(4):205-212.
418. Weiss EA, Franco-Paredes C Travel health and medical kits. Travel medicine 2008, 69-74. Mosby, Philadelphia. 2nd ed. J.S. Keystone, P.E. Kozarsky, D.O. Freedman, H.D. Nothdurft, B.A. Connor (Eds.).
419. Reynolds SA, Levy F, Walker ES Hand sanitizer alert. Emerg Infect Dis 2006, 12(3):527-529.
420. World Health Organization. Global database on blood safety report 2001-2002. Available from: . Geneva: World Health Organization [cited 2008 Jun 30]. http://www.who.int/bloodsafety/GDBS_Report_2001-2002.pdf.
421. Kolars JC Rules of the road: a consumer's guide for travelers seeking health care in foreign lands. J Travel Med 2002, 9(4):198-201.
422. Joint Commission International. c2002-08 [cited 2008 Jun 30]. Available from: . http://www.jointcommissioninternational.org.
423. U.S. Department of State. Medical information for Americans abroad. [cited 2008 Jun 30] Available from: . http://travel.state.gov/travel/tips/brochures/brochures_1215.html.
424. Centers for Medicare and Medicaid Services. Medicare coverage outside the United States. [cited 2008 Jun 30] Available from: . http://www.medicare.gov/Publications/Pubs/pdf/11037.pdf.
425. Lankester T Health care of the long-term traveler. Travel Med Infect Dis 2005, 3(3):143-155.
426. Beny A, Paz A, Potasman I Psychiatric problems in returning travelers: features and associations. J Travel Med 2001, 8(5):243-246.
427. Bhadelia N, Klotman M, Caplivski D The HIV-positive traveler. Am J Med 2007, 120(7):574-580.
428. Reed CM Travel recommendations for older adults. Clin Geriatr Med 2007, 23(3):687-713. ix.
429. Potasman I, Beny A, Seligmann H Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 2000, 7(1):5-9.
430. Patel D, Easmon C, Dow C, et al. Medical repatriation of British diplomats resident overseas. J Travel Med 2000, 7(2):64-69.
431. Palinkas LA, Suedfeld P Psychological effects of polar expeditions. Lancet 2008, 371(9607):153-163.
432. Espino CM, Sundstrom SM, Frick HL, et al. International business travel: impact on families and travellers. Occup Environ Med 2002, 59(5):309-322.
433. Bor R Psychological factors in airline passenger and crew behaviour: a clinical overview. Travel Med Infect Dis 2007, 5(4):207-216.
434. Balaban V Psychological assessment of children in disasters and emergencies: a review. Disasters 2006, 30(2):178-198.
435. Hochedez P, Vinsentini P, Ansart S, et al. Changes in the pattern of health disorders diagnosed among two cohorts of French travelers to Nepal, 17 years apart. J Travel Med 2004, 11(6):341-346.
436. Rolfe M, Tang CM, Sabally S, et al. Psychosis and cannabis abuse in The Gambia. A case-control study. Br J Psychiatry 1993, 163:798-801.
437. Crofford LJ Violence, stress, and somatic syndromes. Trauma Violence Abuse 2007, 8(3):299-313.
438. Urpe M, Buggiani G, Lotti T Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin 2005, 23(4):609-617.